- Home
- SF vs QGEN Comparison
SF vs QGEN Comparison
Compare SF & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SF
- QGEN
- Stock Information
- Founded
- SF 1890
- QGEN 1986
- Country
- SF United States
- QGEN Netherlands
- Employees
- SF N/A
- QGEN N/A
- Industry
- SF Investment Bankers/Brokers/Service
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SF Finance
- QGEN Health Care
- Exchange
- SF Nasdaq
- QGEN Nasdaq
- Market Cap
- SF 12.0B
- QGEN 9.9B
- IPO Year
- SF N/A
- QGEN 1996
- Fundamental
- Price
- SF $91.17
- QGEN $39.41
- Analyst Decision
- SF Hold
- QGEN Buy
- Analyst Count
- SF 8
- QGEN 8
- Target Price
- SF $117.71
- QGEN $49.79
- AVG Volume (30 Days)
- SF 867.9K
- QGEN 1.1M
- Earning Date
- SF 04-23-2025
- QGEN 04-28-2025
- Dividend Yield
- SF 1.96%
- QGEN 3.31%
- EPS Growth
- SF 46.03
- QGEN N/A
- EPS
- SF 6.25
- QGEN 0.37
- Revenue
- SF $4,944,918,000.00
- QGEN $1,978,214,000.00
- Revenue This Year
- SF $16.65
- QGEN $5.15
- Revenue Next Year
- SF $9.85
- QGEN $6.49
- P/E Ratio
- SF $15.02
- QGEN $107.70
- Revenue Growth
- SF 14.36
- QGEN 0.66
- 52 Week Low
- SF $73.51
- QGEN $37.63
- 52 Week High
- SF $120.64
- QGEN $47.93
- Technical
- Relative Strength Index (RSI)
- SF 37.70
- QGEN 49.85
- Support Level
- SF $96.55
- QGEN $39.35
- Resistance Level
- SF $102.78
- QGEN $40.11
- Average True Range (ATR)
- SF 2.94
- QGEN 0.54
- MACD
- SF 0.39
- QGEN 0.18
- Stochastic Oscillator
- SF 22.59
- QGEN 80.88
About SF Stifel Financial Corporation
Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 60% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).